Tue.Mar 19, 2024

article thumbnail

Riding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in China

Fierce Pharma

This year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nat | 2024 marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the Danish drugmaker’s red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nation.

Medicine 325
article thumbnail

AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion Acquisition

MedCity News

AstraZeneca’s Fusion Pharmaceuticals acquisition is the latest in a wave of M&A activity that includes recent deals by Eli Lilly and Bristol Myers Squibb. The lead Fusion program is in mid-stage clinical development for treating advanced prostate cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M, his largest compensation package in years

Fierce Pharma

After a year marked by Gilead's oncology push and an ongoing focus on CAR-T therapies, CEO Daniel O’Day collected his largest total compensation package since the year he arrived at the Califo | The CEO collected his highest total compensation package since his first year in the role in 2019.

289
289
article thumbnail

Providence Chief Nursing Officer: All Hospitals Should Be Using These 3 Tools

MedCity News

In order to effectively address the nursing shortage, hospitals must embrace three key products on the market that has been proven to alleviate nurse burnout, according to Syl Trepanier, chief nursing officer at Providence.

Marketing 119
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

In his final full year as AbbVie's CEO, Richard Gonzalez collects $25.7M in total pay

Fierce Pharma

Guiding AbbVie through an extraordinary decade-plus, riding the success of juggernaut inflammatory disease drug Humira and softening the landing upon its decline, Richard Gonzalez continues to reap | In his final full year as AbbVie’s CEO, Richard Gonzalez pulled down a compensation package worth $25.7 million, according to the company’s proxy filing.

288
288
article thumbnail

AZ agrees $2bn deal to buy radiopharma firm Fusion

pharmaphorum

AstraZeneca upgrades its radiopharma alliance with Fusion Pharma, opting to buy the biotech outright in a deal worth around $2 billion

Pharma 114

More Trending

article thumbnail

In the Era of Value-Based Care, How Are Employer-Provided Health Benefits Evolving?

MedCity News

At the MedCity INVEST conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, health benefits in the context of value-based care will be one of several topics of discussion at the boutique healthcare investment event. Register today!

article thumbnail

IFF, after brief leadership stint under Merck's Frank Clyburn, pawns off pharma solutions business for $2.85B

Fierce Pharma

After a two-year stint under Merck & Co. veteran Frank Clyburn, New York’s International Flavors & Fragrances (IFF) is stripping away a major component of its healthcare persona. | New York's IFF—which dabbles in food, beverage, beauty and pharmaceutical supply chains, among others—has agreed to sell its pharma solutions business to French plant-based ingredient maker Roquette for up to $2.85 billion.

Pharma 264
article thumbnail

NVIDIA doubles down on AI in healthcare with drug discovery deals

Pharmaceutical Technology

In addition to drug discovery deals, NVIDIA also announced partnerships with J&J MedTech and GE Healthcare for genAI in MedTech.

article thumbnail

Takeda's Iclusig wins first-line FDA nod to treat rare Philadelphia chromosome-positive ALL

Fierce Pharma

Twelve years after Takeda's Iclusig (ponatinib) earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S. | Twelve years after Takeda's Iclusig earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S. regulator has signed off on a wider use.

FDA 261
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Biden’s administration initiative aims to advance women’s health conditions

Pharmaceutical Technology

The new initiative aims to spur innovation and mobilisation of sectors to drive women’s health research.

111
111
article thumbnail

PTC, after multiple FDA rejections, will try again with Translarna

Fierce Pharma

Despite Translarna's troubled history at the FDA—and a recent regulatory stumble in Europe—PTC Therapeutics once again hopes to convince U.S. | Despite Translarna's troubled history at the FDA—and a recent regulatory stumble in Europe—PTC Therapeutics once again hopes to convince U.S. regulators of the value of its Duchenne muscular dystrophy therapy.

FDA 235
article thumbnail

Bayer cues up filings for rival to Astellas’ menopause drug

pharmaphorum

New phase 3 data sets up filings for Bayer's non-hormonal menopause symptom treatment elinzanetant and a challenge to Astellas’ first-to-market Veozah

Marketing 109
article thumbnail

Regeneron advances antitrust lawsuit against Novartis with appeals court's backing

Fierce Pharma

Did Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument. | Did Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument.

147
147
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

How Important Is Sales Forecasting Accuracy On Your Sales Team?

Integrity Solutions

As a sales leader have you looked at your forecast and asked questions like these: “Do we have enough opportunities in our forecast to confidently make our goal this quarter/year?” “We may have enough opportunities, but are they large enough in terms of projected revenue? What is our go-get?” “Are we progressing these opportunities through our pipeline process towards close?

Sales 107
article thumbnail

After monumental MASH nod, Madrigal plots $600M stock sale to support Rezdiffra launch

Fierce Pharma

Just a few days ago, Madrigal Pharmaceuticals made history by winning FDA approval for its metabolic dysfunction-associated steatohepatitis (MASH) med Rezdiffra. | Madrigal's Rezdiffra became the first drug approved to treat metabolic dysfunction-associated steatohepatitis (MASH) just a few days ago. Now, the company looks to support the upcoming launch by selling shares.

Sales 130
article thumbnail

NIVIDA and J&J partner on ‘cutting-edge’ AI for surgery

pharmaphorum

Johnson & Johnson has allied with NVIDIA to bring artificial intelligence into operating rooms and accelerate the adoption of digital tech in surgery

105
105
article thumbnail

Novartis acquisition to address inflammation-driven diseases

European Pharmaceutical Review

Under a new deal, Novartis has agreed to acquire US-based biopharma company IFM Therapeutics, for a total of up to $835 million. As part of this new agreement, Novartis has exercised its option to acquire all outstanding capital stock of IFM Due, a subsidiary company of IFM. Therefore, under the acquisition, Novartis has full rights to IFM Due’s portfolio of small molecule Stimulator of Interferon Genes (STING) antagonists, IFM confirmed.

Biopharma 105
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

PAP 2024: John Hoffman Discusses the Health Equity Spotlight Panel

Pharmaceutical Commerce

In an interview with Pharma Commerce Associate Editor Don Tracy, John Hoffman, Principal, Advocate for Success, LLC talks about his 'Health Equity Spotlight' panel and advocacy accomplishments.

Pharma 105
article thumbnail

We Need Your Self-Insured Employer Health Benefits Insights for Our Annual Survey [Sponsored]

MedCity News

Do you advise self-insured employers? The 2023 Benefit Consultant Sentiment INDEX offered robust insights and cast a spotlight on the evolving roles of employers as they navigate the changing healthcare landscape. Your insights offer leading, innovative points of view that can guide employers and peers. Join us for this year’s survey!

Insurance 101
article thumbnail

FDA approves Orchard’s Lenmeldy gene therapy for MLD

Pharmaceutical Technology

The US FDA has granted approval to Orchard Therapeutics' Lenmeldy for specific forms of metachromatic leukodystrophy (MLD).

FDA 98
article thumbnail

GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.

PharmaVoice

Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Biologics driving continuous bioprocessing market expansion

European Pharmaceutical Review

According to research by InsightAce Analytic Pvt. Ltd., the global continuous bioprocessing market is expected to value $1,067.8 million by 2031. While the market was valued at $255.9 million in 2023, the report predicted it will witness a CAGR of 19.72 percent between 2024-2031. The research explained that companies are looking to reduce manufacturing costs and increase productivity, which is driving implementation of this type of bioprocessing.

article thumbnail

How the Analytics of Care Can Balance Workforce Capacity

MedCity News

The always-on, connected health system is not a distant moonshot, but today’s reality.

article thumbnail

KCL researchers develop pipeline to create customisable cell culture device creations

PharmaTimes

The SOL3D pipeline addresses research challenges in relation to equipment, expertise and cost

70
article thumbnail

NVIDIA and J&J partner on ‘cutting-edge’ AI for surgery

pharmaphorum

Johnson & Johnson has allied with NVIDIA to bring artificial intelligence into operating rooms and accelerate the adoption of digital tech in surgery

64
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

ALS Association partners with myTomorrows to improve clinical trial accessibility

PharmaTimes

The fatal motor neurone disease currently does not have a cure available to treat patients

article thumbnail

Traceability technologies tighten supply chain fakery

Pharmaceutical Technology

Rising numbers of counterfeit drugs are entering pharmaceutical supply chains, necessitating advanced track-and-trace systems.

article thumbnail

Can Marketing Save Women’s Healthcare?

Eversana Intouch

Every year, America celebrates and acknowledges the vital role of women in American history with a designated Women’s History Month in March. In recognizing the specific achievements women have made across the years, we also recognize those achievements didn’t come without challenges. And this month, we’re bringing to light the challenges in women’s healthcare that we can help solve and make history together.

article thumbnail

Asieris showcases Phase III win in treating precancerous cervical lesions

Pharmaceutical Technology

Asieris presented positive Phase III results at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, US.

59
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A